Focused On-demand Library for Ubiquitin carboxyl-terminal hydrolase CYLD

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9NQC7

UPID:

CYLD_HUMAN

Alternative names:

Deubiquitinating enzyme CYLD; Ubiquitin thioesterase CYLD; Ubiquitin-specific-processing protease CYLD

Alternative UPACC:

Q9NQC7; O94934; Q7L3N6; Q96EH0; Q9NZX9

Background:

Ubiquitin carboxyl-terminal hydrolase CYLD, also known as Deubiquitinating enzyme CYLD, plays a crucial role in cellular processes by specifically cleaving 'Lys-63'- and linear 'Met-1'-linked polyubiquitin chains. This action is pivotal in NF-kappa-B activation, TNF-alpha-induced necroptosis, and the regulation of cell survival, proliferation, and differentiation. CYLD's ability to regulate microtubule dynamics underscores its importance in cell proliferation, migration, and angiogenesis.

Therapeutic significance:

CYLD's involvement in diseases such as familial cylindromatosis, multiple familial trichoepithelioma 1, Brooke-Spiegler syndrome, and frontotemporal dementia and/or amyotrophic lateral sclerosis 8 highlights its therapeutic potential. Understanding CYLD's role could open doors to novel therapeutic strategies targeting these conditions.